Duality Advisers’s Regenxbio RGNX Stock Holding History

Duality Advisers’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,301	Closed	-$729K	–	802
2021 Q4	$729K	Buy	+22,301	New	+$759K	0.08%	347
2021 Q2	–	Sell	-20,786	Closed	-$709K	–	708
2021 Q1	$709K	Buy	+20,786	New	+$887K	0.06%	404

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Duality Advisers's RGNX Position: Q1 2022 in Review

Duality Advisers sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 22,301 shares — an estimated $729K sold.

Duality Advisers first reported a position in RGNX in Q1 2021 and held it in 2 quarters. The position peaked at $729K in Q4 2021. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

Duality Advisers reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
Duality Advisers sold 22,301 Regenxbio shares in Q1 2022, an estimated $729K.
Duality Advisers first reported a position in Regenxbio in Q1 2021 and held it in 2 quarters.
Duality Advisers's Regenxbio position peaked at $729K in Q4 2021.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on Duality Advisers's 13F filing for Q1 2022, filed 9 May 2022.